Holen Sie sich die Stockscreener-App
3.77
1.89%
0.07
Handel nachbörslich:
4.23
0.46
+12.20%
Schlusskurs vom Vortag:
$3.70
Offen:
$3.7
24-Stunden-Volumen:
521.59K
Relative Volume:
0.82
Marktkapitalisierung:
$236.46M
Einnahmen:
$56.91M
Nettoeinkommen (Verlust:
$-9.06M
KGV:
31.42
EPS:
0.12
Netto-Cashflow:
$-79.97M
1W Leistung:
+12.87%
1M Leistung:
+5.01%
6M Leistung:
-75.94%
1J Leistung:
-29.00%
1-Tages-Spanne:
$3.65
$3.85
1-Wochen-Bereich:
$3.211
$3.95
52-Wochen-Spanne:
$2.9511
$21.88
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - The Manila Times
Macrogenics Earnings Preview - Benzinga
Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com
MacroGenics (NASDAQ:MGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
MacroGenics CEO Scott Koenig to resign early next year - Investing.com India
MacroGenics Announces Leadership Transition - GlobeNewswire
MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday - MarketBeat
MacroGenics Co-Founder Koenig Stepping Down as President, CEO - MarketWatch
MacroGenics CEO Scott Koenig to resign early next year By Investing.com - Investing.com UK
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewswire
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat
MacroGenics (NASDAQ:MGNX) Stock Rating Upgraded by StockNews.com - MarketBeat
Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders - StockTitan
MacroGenics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA - citybiz
MGNXMacroGenics, Inc. Latest Stock News & Market Updates - StockTitan
MacroGenics sells breast cancer treatment to TerSera - The Business Journals
TerSera acquires rights to MacroGenics cancer drug MARGENZA - Investing.com
MacroGenics to Sell Margenza Cancer Drug for $40 Million - MarketWatch
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® - Business Wire
TerSera Therapeutics LLC has entered into an agreement to acquire MARGENZA® from MacroGenics, Inc. for $75 million. - Marketscreener.com
Prepare Yourself for Liftoff: Macrogenics Inc (MGNX) - SETE News
Investor’s Delight: Macrogenics Inc (MGNX) Closes Weak at 3.98, Down -7.01 - The Dwinnex
What was Macrogenics Inc (MGNX)’s performance in the last session? - US Post News
The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - The InvestChronicle
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, - EIN News
Examining Macrogenics Inc (MGNX) stock is warranted - US Post News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc.MGNX - cnhinews.com
Dimensional Fund Advisors LP Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Millennium Management LLC Boosts Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Position Increased by Marshall Wace LLP - MarketBeat
Macrogenics Inc [MGNX] Senior VP and General Counsel makes an insider purchase of 51,395 shares worth 0.8 million. – Knox Daily - Knox Daily
Renaissance Technologies LLC Sells 231,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Perhaps timely catching Macrogenics Inc (MGNX) would be a good idea - SETE News
The Macrogenics Inc (MGNX) had a good session last reading, didn’t it? - US Post News
Macrogenics Inc (MGNX)’s Market Momentum: Closing Strong at 3.19, Up 4.93 - The Dwinnex
MacroGenics' SWOT analysis: vobra-duo safety concerns weigh on stock outlook - Investing.com
MacroGenics' SWOT analysis: vobra-duo safety concerns weigh on stock outlook By Investing.com - Investing.com South Africa
Recent Insider Activity Suggests Potential Gains for Macrogenics Inc (MGNX) - Knox Daily
Frazier Life Sciences Management L.P. Has $12.80 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely - Yahoo Finance
Armistice Capital LLC Purchases 3,600,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Take off with Macrogenics Inc (MGNX): Get ready for trading - SETE News
DRW Securities LLC Takes $56,000 Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - PR Newswire
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX - AccessWire
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com Canada
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - AccessWire
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):